Jason McCarthy

Thomas Yip

Matthew Keller

- Iterum Therapeutics plc filed a prospectus supplement on **October 16, 2025**, for an **At-the-Market Offering** to raise up to an additional **$20,000,000** in gross proceeds by offering up to **21,756,057 ordinary shares**.  **[1659323_0001193125-25-241556_d933718d8k.htm:1]** 
- This offering is conducted under an existing agreement with H.C. Wainwright & Co., LLC, and the company had previously raised approximately **$36.2 million** through this agreement.  **[1659323_0001193125-25-241556_d933718d8k.htm:1]** 
- The company commercially launched its product **ORLYNVAH™** into the U.S. community market in **August 2025** and anticipates modest sales for the remainder of 2025.  **[1659323_0001193125-25-241556_d933718d8k.htm:1]**

Iterum Therapeutics (ITRM)